Neuome Peptides Pte., a Singapore-based company, established an assay-development platform, powered by machine learning and novel, patented algorithms for the quantifiable detection of biomarkers. The company successfully designed specific peptides to bind to pre-established, proven biomarkers for cardiovascular diseases and is currently developing effective diagnostic assays.
The use of small peptides, conjugated with gold nanoparticles, allows a balance of high specificity and sensitivity, giving highly accurate and fast results, the company says.
This is made possible with the product TruHeart, a point-of-care assay to diagnose Acute Coronary Syndrome that can give quantifiable results within 3-5 minutes, using a finger-prick sample to test for the crucial biomarkers, Troponins I and T, and Myoglobin (eventually expanding to D-Dimer and Brain Natriuretic Peptide). It is in the advanced stages of R&D and progressing to global clinical trials. It will be submitted for FDA approval and then introduced to the market upon approval.
According to the U.S. Department of Health & Human Services, a total of 697,000 people died in 2020 died of cardiovascular disease.
This product is aimed at allowing patients to more affordably screen for this potentially deadly condition conveniently early, in their own home, achieving quantifiable results without needing a laboratory. This can more efficiently guide patients to seek appropriate medical attention; those with prevailing heart conditions may also regularly monitor their condition at home.
Its peptide-coated cartridges will cost $2, while the quantitative electronic reader will cost $80, the company says
The company’s Scientific Advisory Board includes leaders in this field, such as Padmashri Balram Bhargava, former director General Indian Council of Medical Research (ICMR).
The company has scheduled clinical trials in five hospitals in India, and is in the process of securing a large site in the U.S. and five sites in Europe.
Photo: Neuome Peptides Pte.
